Silo Pharma Adds Japanese Patent to Expanding Global IP Portfolio for Licensed PTSD Drug
Silo Pharma (Nasdaq: SILO) has strengthened its intellectual property portfolio with a new Japanese patent (No. 7683882) granted to its research partner Columbia University for SPC-15, the company's lead PTSD treatment. The patent, which follows a recent Australian patent grant, covers serotonin 4 receptor agonists for stress treatment.
The intranasal PTSD treatment, exclusively licensed to Silo by Columbia University, gains additional international protection through this patent issuance, supporting the company's development and regulatory strategy for this novel therapy.
Silo Pharma (Nasdaq: SILO) ha rafforzato il proprio portafoglio di propriet脿 intellettuale con un nuovo brevetto giapponese (n. 7683882) concesso al suo partner di ricerca Columbia University per SPC-15, il principale trattamento dell'azienda per il disturbo da stress post-traumatico (PTSD). Il brevetto, che segue una recente concessione in Australia, riguarda gli agonisti del recettore della serotonina 4 per il trattamento dello stress.
Il trattamento intranasale per il PTSD, concesso in licenza esclusiva a Silo dalla Columbia University, ottiene una protezione internazionale aggiuntiva grazie a questo brevetto, a supporto della strategia di sviluppo e regolatoria dell'azienda per questa nuova terapia.
Silo Pharma (Nasdaq: SILO) ha reforzado su cartera de propiedad intelectual con una nueva patente japonesa (n.潞 7683882) otorgada a su socio investigador Columbia University para SPC-15, el tratamiento l铆der de la compa帽铆a para el TEPT. La patente, que sigue a una reciente concesi贸n en Australia, cubre agonistas del receptor de serotonina 4 para el tratamiento del estr茅s.
El tratamiento intranasal para el TEPT, licenciado en exclusiva a Silo por Columbia University, obtiene una protecci贸n internacional adicional con esta concesi贸n de patente, apoyando la estrategia de desarrollo y regulatoria de la compa帽铆a para esta novedosa terapia.
Silo Pharma (Nasdaq: SILO)電� 欤检殧 PTSD 旃橂鞝� SPC-15鞐� 雽�頃� 鞐瓣惮 韺岉姼雱堨澑 旎熂牍勳晞 雽�頃欔祼鞐� 攵�鞐悳 靸堧鞖� 鞚茧掣 韸鬼棃(氩堩樃 7683882)搿� 歆�鞁濎灛靷瓣秾 韽姼韽措Μ鞓るゼ 臧曧檾頄堨姷雼堧嫟. 斓滉芳 順胳＜ 韸鬼棃 攵�鞐棎 鞚挫柎 雮橃槰 鞚� 韸鬼棃電� 鞀ろ姼霠堨姢 旃橂毳� 鞙勴暅 靹鸽韱犽媽4 靾橃毄觳� 鞛戩毄鞝滊ゼ 韽暔頃╇媹雼�.
旎熂牍勳晞 雽�頃欔祼搿滊秬韯� Silo鞐� 霃呾爯鞝侅溂搿� 霛检澊靹犾姢霅� 鞚� 牍勱皶 韴棳 PTSD 旃橂鞝滊姅 鞚措矆 韸鬼棃 霌彪鞙茧 甑牅鞝� 氤错樃 氩旍渼毳� 頇曥灔頃橃棳 鞚� 順侅嫚鞝� 旃橂鞝滌潣 臧滊皽 氚� 攴滌牅 鞝勲灥鞚� 霋冯皼旃暕雼堧嫟.
Silo Pharma (Nasdaq: SILO) a renforc茅 son portefeuille de propri茅t茅 intellectuelle avec un nouveau brevet japonais (n掳 7683882) accord茅 脿 son partenaire de recherche Columbia University pour SPC-15, le traitement phare de la soci茅t茅 contre le PTSD. Le brevet, qui fait suite 脿 une r茅cente d茅livrance en Australie, couvre les agonistes du r茅cepteur de la s茅rotonine 4 pour le traitement du stress.
Le traitement intranasal contre le PTSD, licenci茅 en exclusivit茅 脿 Silo par Columbia University, b茅n茅ficie d'une protection internationale suppl茅mentaire gr芒ce 脿 cette d茅livrance de brevet, soutenant la strat茅gie de d茅veloppement et r茅glementaire de la soci茅t茅 pour cette th茅rapie innovante.
Silo Pharma (Nasdaq: SILO) hat sein geistiges Eigentum mit einem neuen japanischen Patent (Nr. 7683882) gest盲rkt, das seinem Forschungspartner Columbia University f眉r SPC-15, die f眉hrende PTSD-Behandlung des Unternehmens, erteilt wurde. Das Patent, das einer k眉rzlichen Patenterteilung in Australien folgt, deckt Serotonin-4-Rezeptor-Agonisten zur Stressbehandlung ab.
Die intranasale PTSD-Behandlung, die von der Columbia University exklusiv an Silo lizenziert wurde, erh盲lt durch diese Patenterteilung zus盲tzlichen internationalen Schutz und unterst眉tzt die Entwicklungs- und Zulassungsstrategie des Unternehmens f眉r diese neuartige Therapie.
- Secured new Japanese patent protection for lead PTSD drug SPC-15
- Expanding international IP portfolio with recent Australian and Japanese patents
- Exclusive licensing agreement with Columbia University for the technology
- None.
SARASOTA, FL, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (鈥淪ilo鈥� or 鈥渢he Company), a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company, today announced that the Japan Patent Office has granted patent number 7683882 to Silo鈥檚 research and licensing partner Columbia University for the invention titled 鈥淧rophylactic efficacy of serotonin 4 receptor agonists against stress,鈥� exclusively licensed to Silo by Columbia University. Columbia University recently received an Australian patent for the same invention.
The patent reinforces protection for Silo鈥檚 lead asset, SPC-15, an intranasal treatment targeting post-traumatic stress disorder (PTSD), originally developed by Columbia University.
鈥淭his Japanese patent adds another layer of protection for SPC-15, adding to our high-value international IP portfolio,鈥� said Silo CEO Eric Weisblum. 鈥淥ur expanding patent library is a cornerstone in the ongoing development and regulatory strategy for our novel PTSD therapy.鈥�
About SPC-15
SPC-15 is an intranasal serotonin 5-HT4 receptor agonist aimed at treating stress-induced psychiatric disorders such as PTSD and anxiety. With its potential eligibility for the FDA鈥檚 streamlined 505(b)(2) regulatory pathway, SPC-15 offers a promising approach to accelerate the approval process. Silo Pharma is collaborating with Columbia University to conduct preclinical studies and has exclusive global rights to the development and commercialization of SPC-15.
About Silo Pharma
Silo Pharma is a diversified developmental-stage biopharmaceutical and cryptocurrency treasury company. Its therapeutic focus is on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company鈥檚 portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer鈥檚 disease and multiple sclerosis. Silo鈥檚 research is conducted in collaboration with leading universities and laboratories.聽
Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning of the 鈥渟afe harbor鈥� provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified using words 鈥渃ould鈥�, 鈥渂elieve鈥�, 鈥渁nticipate鈥�, 鈥渋ntend鈥�, 鈥渆stimate鈥�, 鈥渆xpect鈥�, 鈥渕ay鈥�, 鈥渃ontinue鈥�, 鈥減redict鈥�, 鈥減otential鈥�, and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Silo Pharma, Inc. (鈥淪ilo鈥� or 鈥渢he Company鈥�) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company鈥檚 technology platforms, retaining and expanding the Company鈥檚 customer base, fluctuations in consumer spending on the Company鈥檚 products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this press release, whether as a result of new information, future events, or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events except as required by law.
Contact
800-705-0120
FAQ
What patent did Silo Pharma (SILO) receive in Japan for its PTSD treatment?
What is Silo Pharma's SPC-15 treatment designed for?
How many countries have granted patents for Silo Pharma's PTSD treatment?
Who developed the PTSD treatment that Silo Pharma is commercializing?
